A Comprehensive Review on the Cardioprotective and Nephroprotective Effects of Semaglutide, and Its Therapeutic Efficacy and Mechanisms in Cardiorenal Syndrome

Lu Ye,1– 3,* Pusong Tang,1– 3,* Haixu Wan,1– 3,* Xing Zhong,2– 4 Xin Chen,2– 4 Changzhao Liu,2– 4 Rui Huang2– 4 1Health Science Center, Hubei Minzu University, Enshi, Hubei, People’s Republic of China; 2Hubei Selenium and Human Health Institute, The Central Hospital of Enshi...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Ye L, Tang P, Wan H, Zhong X, Chen X, Liu C, Huang R
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Dove Medical Press 2026-03-01
Sarja:	Drug Design, Development and Therapy
Aiheet:	Semaglutide (SEM) a GLP-1 receptor agonist (GLP-1RA) is commonly used to manage blood glucose and weight in type 2 diabetes patients(T2DM). Research indicates that SEM protects the kidneys and heart by slowing eGFR decline reducing proteinuria enhancing cardiac outcomes and lowering cardiovascular risk. These benefits are linked to various mechanisms
Linkit:	https://www.dovepress.com/a-comprehensive-review-on-the-cardioprotective-and-nephroprotective-ef-peer-reviewed-fulltext-article-DDDT
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!